



**Date: 21.05.2026**

To,  
Department of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai – 400 001.

Ref: Scrip Code: 526075

**Subject: Outcome of Board Meeting held on 21<sup>st</sup> May, 2026.**

Dear Sir,

With reference to above and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at their meeting held today have inter-alia considered and approved:

1. Pursuant to Regulation 33 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015, we are herewith submitting the following:

a) Standalone Audited Financial Results for the Quarter and Year ended on March 31, 2026 along with statement of Assets and Liabilities and Cash Flow Statement for the year ended on March 31, 2026.

b) Independent Audit Report by Statutory Auditors of the Company on Standalone Audited Financial Results for the Quarter and Year ended on March 31, 2026.

2. Declaration on Auditor's Report with unmodified opinion pursuant to Regulation 33 (3)(d) of the Listing Regulations signed by Mr. Amit Mukesh Shah, Director of the Company.

The meeting of the Board of Directors commenced at 6 : 30 Pm and concluded at 7: 55 Pm.

This is for your information and record.

Thanking You

Yours Faithfully

FOR REKVINA LABORATORIES LIMITED

  
Amit Mukesh Shah  
Chairman and Managing Director  
DIN: 01993211

**REKVINA LABORATORIES LIMITED**  
**CIN: L24231GJ1988PLC011458**  
**Standalone Financial Result for the period ended on 31 March 2026**

Rs. in Lacs

Sr No	Particulars	Quarter Ended			Period ended	Year Ended
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		Un Audited	Un Audited	Un Audited	Un Audited	Audited
I	<b>Income</b>					
	Revenue From Operations	72.36	34.56	-	126.54	-
	<b>Total Income (I)</b>	72.36	34.56	-	126.54	-
II	<b>Expenses</b>					
	Purchases of Stock-in-Trade	67.26	33.06	-	118.16	-
	Employee benefits expense	6.41	10.11	3.35	22.99	4.30
	Other expenses	4.74	3.78	0.93	10.86	9.41
	<b>Total expenses (II)</b>	78.41	46.95	4.28	152.01	13.71
III	<b>Profit/(loss) before tax (I-II)</b>	(6.05)	(12.39)	(4.28)	(25.47)	(13.71)
IV	<b>Tax expenses</b>					
	Current tax	-	-	-	-	-
	<b>Total Tax expense (IV)</b>	(6.05)	(12.39)	(4.28)	(25.47)	(13.71)
V	<b>Profit/(loss) after tax for the period (III-IV)</b>					
VI	<b>Other Comprehensive Income</b>					
	<b>Total Other Comprehensive Income (VI)</b>	-	-	-	-	-
VII	<b>Total Comprehensive Income for the period (V+VI)</b>	(6.05)	(12.39)	(4.28)	(25.47)	(13.71)
VIII	<b>Earnings per equity share</b>					
	Basic	(0.10)	(0.21)	(0.07)	(0.42)	(0.23)
	Diluted	(0.10)	(0.21)	(0.07)	(0.42)	(0.23)

For and on behalf of Board of Directors,  
**Rekvina Laboratories Limited**

  
**Mr. Amit Mukesh Shah**  
 Managing Director



DIN: 01993211

Place: Vadodara

Date: 21.05.2026

**REKVINA LABORATORIES LIMITED**  
**CIN: L24231GJ1988PLC011458**  
**Standalone Financial Result for the period ended on 31 March 2026**

Rs. in Lacs

Particulars	Note No	As at 31 March 2026	As at 31 March 2025
<b>ASSETS</b>			
Non-current assets			
Current assets			
Financial Assets		59.65	-
Trade receivables		1.53	2.51
Cash and cash equivalents		57.71	0.41
Other current assets		<b>118.89</b>	<b>2.92</b>
<b>Total Current Assets</b>		<b>118.89</b>	<b>2.92</b>
<b>Total Assets</b>			
<b>EQUITY and LIABILITIES</b>			
Equity Share Capital		301.40	301.40
Other Equity		(424.22)	(335.24)
<b>Total Equity</b>		<b>(122.82)</b>	<b>(33.84)</b>
<b>Current liabilities</b>			
Financial Liabilities		147.27	25.30
Borrowings		-	-
Trade Payables		-	-
- total outstanding dues of micro enterprises and small enterprises		39.44	10.71
- total outstanding dues of others		55.00	0.75
Other current liabilities		<b>241.71</b>	<b>36.76</b>
<b>Total Current liabilities</b>		<b>241.71</b>	<b>36.76</b>
<b>Total liabilities</b>		<b>118.89</b>	<b>2.92</b>
<b>Total Equity and Liabilities</b>			

For and on behalf of Board of Directors,  
**Rekvina Laboratories Limited**

  
**Mr. Amit Mukesh Shah**  
 Managing Director



DIN: 01993211

Place: Vadodara  
 Date: 21.05.2026

**REKVINA LABORATORIES LIMITED**

CIN: L24231GJ1988PLC011458


**Standalone Cash Flow Statement for the period ended on 31 March 2026**

Rs. in Lacs

Particulars	Note No	For Period ended 31 March 2026	For Period ended 31 March 2025
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit for the year		(25.47)	(13.71)
<b>Adjustments for:</b>			
Depreciation and amortisation		-	-
(Gain)/Loss on disposal of property, plant and equipment		-	-
(Gain)/Loss on disposal of Investments		-	-
(Gain)/Loss on investments measured at fair value through profit and loss		-	-
Provision for Income tax		-	-
<b>Operating profit before working capital changes</b>		<b>(25.47)</b>	<b>(13.71)</b>
<b>Adjustment for (increase) / decrease in operating assets</b>			
Trade receivables		(59.65)	-
Other assets		(56.90)	(0.74)
<b>Adjustment for (Increase) / decrease in operating liabilities</b>			
Trade payables		28.72	(0.72)
Employee benefit obligation		-	-
Other Liabilities		53.87	(4.02)
<b>Cash generated from operations</b>		<b>(59.43)</b>	<b>(19.19)</b>
Income tax paid (net)		-	-
<b>Net cash generated by operating activities</b>		<b>(59.43)</b>	<b>(19.19)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
<b>Net cash (used in) / generated by investing activities</b>		<b>-</b>	<b>-</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Proceeds from short term borrowings		122.59	20.74
Other Equity		(64.13)	-
<b>Net cash used in financing activities</b>		<b>58.46</b>	<b>20.74</b>
Net increase / (decrease) in cash and cash equivalents		(0.97)	1.55
Cash and cash equivalents at the beginning of the year		2.51	0.95
Exchange gain loss on Cash and cash equivalents		-	-
<b>Cash and cash equivalents at the end of the year</b>		<b>1.54</b>	<b>2.50</b>

For and on behalf of Board of Directors,  
**Rekvina Laboratories Limited**

  
**Mr. Amit Mukesh Shah**  
 Managing Director  
 DIN: 01993211



Place: Vadodara  
 Date: 21.05.2026


- 1 The above audited financial results were reviewed by the audit committee and approved by the Board of Directors at their respective meetings held on May 21, 2026. The said result have also been audited by the statutory auditors of the Company.
- 2 The above audited financial results are also available on the company's website [www.rekvinlaboratories.com](http://www.rekvinlaboratories.com).
- 3 The company operates in one single reportable business segment and geographical segment in India.
- 4 The Board of Directors has not recommended any dividend for the financial year ended March 31, 2026.
- 5 This statement is prepared as per Indian Accounting Standards (IND AS) notified under section 133 under Companies Act, 2013 read with Companies Act 2015 (Indian Accounting Standard Rules) as ammended and as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 6 During the year, the Board of Directors approved increase in the Authorised Share Capital of the Company from ₹3,50,00,000/- divided into 70,00,000 equity shares of ₹5/- each to ₹6,00,00,000/- divided into 1,20,00,000 equity shares of ₹5/- each, subject to approval of shareholders and other applicable approvals.
- 7 The Board of Directors approved execution of Share Exchange and Purchase Agreement for acquisition of 100% equity share capital of Radiant Parenterals Limited for an aggregate consideration of ₹4,62,77,500/-. The consideration shall be discharged by way of issuance of 46,27,750 equity shares of the Company on preferential basis for consideration other than cash, subject to approval of shareholders and other regulatory approvals.
- 8 The Board of Directors also approved execution of Share Subscription Agreement with Amitkumar Arunkumar Rao and Amitkumar Arunkumar Rao HUF for issuance of 4,60,000 equity shares of the Company on preferential basis for cash consideration aggregating to ₹46,00,000/-, subject to approval of shareholders and other applicable approvals.
- 9 The aforesaid acquisition transaction has triggered an open offer obligation under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by the proposed acquirers.
- 10 The results for the quarter ended March 31, 2026 and March 31, 2025 are not separately audited. These figures are calculated by taking the audited financial results for the full year and subtracting the figures for the first nine months (April to December) that were already published.  
The figures for the first nine months of the current and previous financial year (up to December 31) were reviewed by the auditors, as required under SEBI's Listing Regulations, but were not audited.

- 11 Previous period's / year figures have been regrouped / rearranged wherever consider necessary to confirm to the current period's / year classification.

Place: Vadodara  
Date: 21.05.2026

For and on behalf of Board of Directors,  
**Rekvina Laboratories Limited**

  
**Mr. Amit Mukesh Shah**  
Managing Director  
DIN: 01993211



**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

To

The Board of Directors  
Rekvina Laboratories Limited

**Report on the audit of the Annual Financial Results and review of the Quarterly Financial Results**

We have:

(a) audited the accompanying Statement of Annual Financial Results of Rekvina Laboratories Limited ("the Company") for the year ended **31st March 2026** ("the Statement"), and

(b) reviewed the Financial Results for the quarter ended **31st March 2026**, which are included in the accompanying Statement of Financial Results for the quarter and year ended **31st March 2026** ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Audit Opinion on the Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Annual Financial Results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the net profit/loss and other comprehensive income and other financial information of the Company for the year ended **31st March 2026**.

(b) Conclusion on the Quarterly Financial Results

- With respect to the Financial Results for the quarter ended **31st March 2026**, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that cause us to believe that the Financial Results for the quarter ended 31st March 2026, prepared in accordance with the recognition and measurement principle laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



### **Basis for Opinion**

We conducted our audit of the Annual Financial Results in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013. Our responsibilities under those standards are further described in the Auditor's Responsibilities section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI), and we have fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence obtained is sufficient and appropriate to provide a basis for our opinion.

### **Management's Responsibilities for the Financial Results**

This Statement, which includes the Annual Financial Results and the results for the quarter ended **31st March 2026**, has been Compiled from the related audited Standalone Financial Statements. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility includes the preparation and presentation of Annual Financial Statements for the quarter and year ended March 31, 2025. This responsibility also maintenance of adequate accounting records, selection and application of appropriate accounting policies, safeguarding the assets of the Company, and detecting and preventing frauds and other irregularities.

### **Auditor's Responsibilities**

#### **(a) Audit of the Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the Annual Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the SAs will always detect a material misstatement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

#### **(b) Review of the Quarterly Financial Results**



- We conducted our review of the Statement for the quarter ended **31st March 2026** in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.
- A review is substantially less in scope than an audit and does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on the quarterly financial results.
- Based on our review conducted as above, nothing has come to our attention that causes us to believe that the quarterly financial results prepared in accordance with the applicable Indian Accounting Standards and other recognized accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### Other Matters

- The Statement includes the results for the quarter ended **31st March 2026** being the balancing figure between audited figures in respect of the full financial year and the published year-to-date figures up to the third quarter of the current financial year which were subject to limited review by us.

Date: 21.05.2026

Place: Vadodara



FOR Y. M. SHAH & Co.  
Chartered Accountants  
F. R. No.: 114124W

  
Harsh Shah  
Partner

M. No. 188123

UDIN: 26188123RYOEQG2714



**Date: 21.05.2026**

To,  
Department of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai – 400 001.

Ref: Scrip Code: 526075

**Subject: Declaration pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**



Dear Sir/Madam,

In terms of Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declared that Statutory Auditors of the Company, M/s. Y. M. Shah, Chartered Accountants (Firm Registration No.: 114124W) have issued an Audit Report with unmodified opinion on Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026.

Thanking You

Yours Faithfully

**FOR REKVINA LABORATORIES LIMITED**

**Amit Mukesh Shah**  
**Chairman and Managing Director**  
**DIN: 01993211**

CIN: L24231GJ1988PLC01145

Regd. Office: 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda -39007

Email Id: info@rekvinalaboratories.com, rekvinalimited@gmail.com

Cont. No.: 0265-2362966